nodes	percent_of_prediction	percent_of_DWPC	metapath
Lamivudine—ABCC3—Cyclosporine—psoriasis	0.0807	0.125	CbGbCtD
Lamivudine—ABCC1—Cyclosporine—psoriasis	0.0495	0.0766	CbGbCtD
Lamivudine—ABCC2—Mycophenolate mofetil—psoriasis	0.0484	0.0748	CbGbCtD
Lamivudine—ABCG2—Mycophenolate mofetil—psoriasis	0.0437	0.0676	CbGbCtD
Lamivudine—ABCC3—Methotrexate—psoriasis	0.0427	0.066	CbGbCtD
Lamivudine—ABCC2—Cyclosporine—psoriasis	0.0367	0.0567	CbGbCtD
Lamivudine—ABCG2—Hydrocortisone—psoriasis	0.0351	0.0543	CbGbCtD
Lamivudine—ABCG2—Cyclosporine—psoriasis	0.0331	0.0512	CbGbCtD
Lamivudine—ABCC4—Methotrexate—psoriasis	0.0326	0.0504	CbGbCtD
Lamivudine—SLC22A6—Cyclosporine—psoriasis	0.0268	0.0415	CbGbCtD
Lamivudine—ABCC1—Methotrexate—psoriasis	0.0262	0.0405	CbGbCtD
Lamivudine—ABCC2—Dexamethasone—psoriasis	0.0241	0.0373	CbGbCtD
Lamivudine—ABCG2—Dexamethasone—psoriasis	0.0218	0.0337	CbGbCtD
Lamivudine—ABCC2—Methotrexate—psoriasis	0.0194	0.03	CbGbCtD
Lamivudine—ABCG2—Methotrexate—psoriasis	0.0175	0.0271	CbGbCtD
Lamivudine—ABCB1—Mycophenolate mofetil—psoriasis	0.0158	0.0244	CbGbCtD
Lamivudine—SLC22A6—Methotrexate—psoriasis	0.0142	0.022	CbGbCtD
Lamivudine—ABCB1—Betamethasone—psoriasis	0.0135	0.0209	CbGbCtD
Lamivudine—ABCB1—Prednisolone—psoriasis	0.0133	0.0206	CbGbCtD
Lamivudine—ABCB1—Hydrocortisone—psoriasis	0.0127	0.0196	CbGbCtD
Lamivudine—ABCB1—Prednisone—psoriasis	0.0126	0.0195	CbGbCtD
Lamivudine—ABCB1—Cyclosporine—psoriasis	0.012	0.0185	CbGbCtD
Lamivudine—ABCB1—Dexamethasone—psoriasis	0.00787	0.0122	CbGbCtD
Lamivudine—ABCB1—Methotrexate—psoriasis	0.00632	0.00978	CbGbCtD
Lamivudine—NT5C—Purine catabolism—CAT—psoriasis	0.00497	0.134	CbGpPWpGaD
Lamivudine—NT5C—Purine metabolism—CAT—psoriasis	0.00191	0.0516	CbGpPWpGaD
Lamivudine—PGK1—HIF-1-alpha transcription factor network—CP—psoriasis	0.00152	0.0411	CbGpPWpGaD
Lamivudine—NT5C—Nucleotide metabolism—CAT—psoriasis	0.00096	0.0259	CbGpPWpGaD
Lamivudine—CMPK1—Nucleotide metabolism—CAT—psoriasis	0.00096	0.0259	CbGpPWpGaD
Lamivudine—PGK1—HIF-1-alpha transcription factor network—LEP—psoriasis	0.000695	0.0188	CbGpPWpGaD
Lamivudine—DCK—Purine metabolism—CAT—psoriasis	0.000688	0.0186	CbGpPWpGaD
Lamivudine—NME2—Nucleotide metabolism—CAT—psoriasis	0.000665	0.018	CbGpPWpGaD
Lamivudine—ABCC3—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000659	0.0178	CbGpPWpGaD
Lamivudine—PGK1—HIF-1-alpha transcription factor network—NOS2—psoriasis	0.000648	0.0175	CbGpPWpGaD
Lamivudine—PGK1—HIF-2-alpha transcription factor network—VEGFA—psoriasis	0.000638	0.0172	CbGpPWpGaD
Lamivudine—ABCC4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.00062	0.0167	CbGpPWpGaD
Lamivudine—ABCB1—Allograft Rejection—IL22—psoriasis	0.000594	0.016	CbGpPWpGaD
Lamivudine—ABCC2—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000523	0.0141	CbGpPWpGaD
Lamivudine—NME1—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	0.000521	0.0141	CbGpPWpGaD
Lamivudine—NME1—Nucleotide metabolism—CAT—psoriasis	0.000504	0.0136	CbGpPWpGaD
Lamivudine—NME1—Fluticasone Propionate—Clobetasol propionate—psoriasis	0.0005	0.0847	CbGdCrCtD
Lamivudine—PGK1—HIF-1-alpha transcription factor network—JUN—psoriasis	0.000429	0.0116	CbGpPWpGaD
Lamivudine—NME1—Fluticasone Propionate—Fluocinonide—psoriasis	0.0004	0.0678	CbGdCrCtD
Lamivudine—NME1—Fluticasone Propionate—Beclomethasone—psoriasis	0.0004	0.0678	CbGdCrCtD
Lamivudine—NME1—Fluticasone Propionate—Fluocinolone Acetonide—psoriasis	0.000389	0.0659	CbGdCrCtD
Lamivudine—ABCG2—Iron uptake and transport—CP—psoriasis	0.00038	0.0103	CbGpPWpGaD
Lamivudine—ABCC3—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000379	0.0102	CbGpPWpGaD
Lamivudine—PGK1—HIF-1-alpha transcription factor network—VEGFA—psoriasis	0.000375	0.0101	CbGpPWpGaD
Lamivudine—DCK—Nucleotide metabolism—CAT—psoriasis	0.000346	0.00933	CbGpPWpGaD
Lamivudine—CMPK1—Metabolism—NDUFA5—psoriasis	0.000341	0.00921	CbGpPWpGaD
Lamivudine—NT5C—Metabolism—NDUFA5—psoriasis	0.000341	0.00921	CbGpPWpGaD
Lamivudine—PCYT2—Metabolism—NDUFA5—psoriasis	0.000341	0.00921	CbGpPWpGaD
Lamivudine—DCK—Desoximetasone—Clobetasol propionate—psoriasis	0.000331	0.0561	CbGdCrCtD
Lamivudine—DCK—Diflorasone—Clobetasol propionate—psoriasis	0.000321	0.0545	CbGdCrCtD
Lamivudine—PCYT2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	0.000318	0.00859	CbGpPWpGaD
Lamivudine—SLC22A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—psoriasis	0.000313	0.00844	CbGpPWpGaD
Lamivudine—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.0003	0.0081	CbGpPWpGaD
Lamivudine—NT5C—Metabolism—CYP2S1—psoriasis	0.00029	0.00783	CbGpPWpGaD
Lamivudine—PCYT2—Metabolism—CYP2S1—psoriasis	0.00029	0.00783	CbGpPWpGaD
Lamivudine—CMPK1—Metabolism—CYP2S1—psoriasis	0.00029	0.00783	CbGpPWpGaD
Lamivudine—PGK1—Metabolism—NDUFA5—psoriasis	0.000278	0.00751	CbGpPWpGaD
Lamivudine—DCK—Retinoblastoma (RB) in Cancer—PCNA—psoriasis	0.000273	0.00737	CbGpPWpGaD
Lamivudine—ABCG2—HIF-1-alpha transcription factor network—CP—psoriasis	0.00027	0.00728	CbGpPWpGaD
Lamivudine—DCK—Desoximetasone—Beclomethasone—psoriasis	0.000265	0.0449	CbGdCrCtD
Lamivudine—DCK—Desoximetasone—Fluocinonide—psoriasis	0.000265	0.0449	CbGdCrCtD
Lamivudine—ABCC3—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000264	0.00712	CbGpPWpGaD
Lamivudine—PCYT1A—Metabolism—NDUFA5—psoriasis	0.000259	0.00698	CbGpPWpGaD
Lamivudine—DCK—Desoximetasone—Fluocinolone Acetonide—psoriasis	0.000258	0.0437	CbGdCrCtD
Lamivudine—DCK—Diflorasone—Beclomethasone—psoriasis	0.000257	0.0436	CbGdCrCtD
Lamivudine—DCK—Diflorasone—Fluocinonide—psoriasis	0.000257	0.0436	CbGdCrCtD
Lamivudine—ABCC4—Hemostasis—SERPINB8—psoriasis	0.000257	0.00693	CbGpPWpGaD
Lamivudine—DCK—Diflorasone—Fluocinolone Acetonide—psoriasis	0.00025	0.0424	CbGdCrCtD
Lamivudine—ABCB1—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000246	0.00663	CbGpPWpGaD
Lamivudine—PCYT1A—Metabolism of lipids and lipoproteins—CARM1—psoriasis	0.000241	0.00651	CbGpPWpGaD
Lamivudine—PGK1—Metabolism—CYP2S1—psoriasis	0.000237	0.00639	CbGpPWpGaD
Lamivudine—NME2—Metabolism—NDUFA5—psoriasis	0.000237	0.00639	CbGpPWpGaD
Lamivudine—SLC22A6—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—psoriasis	0.000235	0.00635	CbGpPWpGaD
Lamivudine—PCYT1A—Metabolism—CYP2S1—psoriasis	0.00022	0.00594	CbGpPWpGaD
Lamivudine—NME1—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	0.000212	0.00573	CbGpPWpGaD
Lamivudine—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000209	0.00565	CbGpPWpGaD
Lamivudine—NME2—Validated targets of C-MYC transcriptional activation—TP53—psoriasis	0.000209	0.00563	CbGpPWpGaD
Lamivudine—ABCC1—S1P1 pathway—VEGFA—psoriasis	0.000204	0.00551	CbGpPWpGaD
Lamivudine—NME2—Metabolism—CYP2S1—psoriasis	0.000201	0.00543	CbGpPWpGaD
Lamivudine—ABCC3—NRF2 pathway—TGFA—psoriasis	0.000198	0.00533	CbGpPWpGaD
Lamivudine—SLC22A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—psoriasis	0.000196	0.00529	CbGpPWpGaD
Lamivudine—ABCC4—NRF2 pathway—TGFA—psoriasis	0.000186	0.00502	CbGpPWpGaD
Lamivudine—SLC22A1—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—psoriasis	0.000183	0.00493	CbGpPWpGaD
Lamivudine—NME1—Fluticasone Propionate—Betamethasone—psoriasis	0.000182	0.0309	CbGdCrCtD
Lamivudine—NME1—Fluticasone Propionate—Dexamethasone—psoriasis	0.000182	0.0309	CbGdCrCtD
Lamivudine—NME1—Metabolism—NDUFA5—psoriasis	0.000179	0.00484	CbGpPWpGaD
Lamivudine—NME1—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	0.000178	0.00481	CbGpPWpGaD
Lamivudine—NME1—Fluticasone Propionate—Triamcinolone—psoriasis	0.000178	0.0302	CbGdCrCtD
Lamivudine—NME1—Validated targets of C-MYC transcriptional activation—TP53—psoriasis	0.000158	0.00427	CbGpPWpGaD
Lamivudine—ABCC2—NRF2 pathway—TGFA—psoriasis	0.000157	0.00423	CbGpPWpGaD
Lamivudine—NME1—Metabolism—CYP2S1—psoriasis	0.000153	0.00412	CbGpPWpGaD
Lamivudine—PCYT2—Metabolism of lipids and lipoproteins—APOE—psoriasis	0.000152	0.00411	CbGpPWpGaD
Lamivudine—ABCB1—HIF-1-alpha transcription factor network—CP—psoriasis	0.000146	0.00393	CbGpPWpGaD
Lamivudine—SLC22A3—SLC-mediated transmembrane transport—CP—psoriasis	0.000142	0.00383	CbGpPWpGaD
Lamivudine—NT5C—Metabolism—CARM1—psoriasis	0.000142	0.00383	CbGpPWpGaD
Lamivudine—CMPK1—Metabolism—CARM1—psoriasis	0.000142	0.00383	CbGpPWpGaD
Lamivudine—PCYT2—Metabolism—CARM1—psoriasis	0.000142	0.00383	CbGpPWpGaD
Lamivudine—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000141	0.00381	CbGpPWpGaD
Lamivudine—PCYT2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	0.000133	0.00358	CbGpPWpGaD
Lamivudine—DCK—Desoximetasone—Hydrocortisone—psoriasis	0.00013	0.0221	CbGdCrCtD
Lamivudine—ABCC3—Fluoropyrimidine Activity—TP53—psoriasis	0.000127	0.00342	CbGpPWpGaD
Lamivudine—DCK—Metabolism—NDUFA5—psoriasis	0.000123	0.00332	CbGpPWpGaD
Lamivudine—ABCG2—HIF-1-alpha transcription factor network—LEP—psoriasis	0.000123	0.00332	CbGpPWpGaD
Lamivudine—DCK—Desoximetasone—Betamethasone—psoriasis	0.000121	0.0205	CbGdCrCtD
Lamivudine—DCK—Desoximetasone—Dexamethasone—psoriasis	0.000121	0.0205	CbGdCrCtD
Lamivudine—ABCC4—Fluoropyrimidine Activity—TP53—psoriasis	0.000119	0.00321	CbGpPWpGaD
Lamivudine—NME1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	0.000118	0.00319	CbGpPWpGaD
Lamivudine—DCK—Desoximetasone—Triamcinolone—psoriasis	0.000118	0.02	CbGdCrCtD
Lamivudine—DCK—Diflorasone—Betamethasone—psoriasis	0.000117	0.0199	CbGdCrCtD
Lamivudine—DCK—Diflorasone—Dexamethasone—psoriasis	0.000117	0.0199	CbGdCrCtD
Lamivudine—PGK1—Metabolism—CARM1—psoriasis	0.000116	0.00312	CbGpPWpGaD
Lamivudine—PCYT1A—Metabolism of lipids and lipoproteins—APOE—psoriasis	0.000115	0.00311	CbGpPWpGaD
Lamivudine—DCK—Diflorasone—Triamcinolone—psoriasis	0.000115	0.0194	CbGdCrCtD
Lamivudine—ABCG2—HIF-1-alpha transcription factor network—NOS2—psoriasis	0.000115	0.00309	CbGpPWpGaD
Lamivudine—NME1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	0.000114	0.00307	CbGpPWpGaD
Lamivudine—ABCG2—HIF-2-alpha transcription factor network—VEGFA—psoriasis	0.000113	0.00304	CbGpPWpGaD
Lamivudine—ABCB1—Allograft Rejection—HLA-C—psoriasis	0.000113	0.00304	CbGpPWpGaD
Lamivudine—DCK—Desoximetasone—Prednisone—psoriasis	0.000112	0.019	CbGdCrCtD
Lamivudine—ABCB1—Allograft Rejection—IL13—psoriasis	0.000112	0.00302	CbGpPWpGaD
Lamivudine—NME1—Levonorgestrel—Hydrocortisone—psoriasis	0.000112	0.0189	CbGdCrCtD
Lamivudine—DCK—Desoximetasone—Prednisolone—psoriasis	0.000109	0.0185	CbGdCrCtD
Lamivudine—DCK—Diflorasone—Prednisone—psoriasis	0.000109	0.0184	CbGdCrCtD
Lamivudine—PCYT1A—Metabolism—CARM1—psoriasis	0.000107	0.0029	CbGpPWpGaD
Lamivudine—SLC22A6—SLC-mediated transmembrane transport—CP—psoriasis	0.000107	0.00288	CbGpPWpGaD
Lamivudine—DCK—Diflorasone—Prednisolone—psoriasis	0.000106	0.018	CbGdCrCtD
Lamivudine—DCK—Metabolism—CYP2S1—psoriasis	0.000105	0.00282	CbGpPWpGaD
Lamivudine—NME1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	0.000103	0.00279	CbGpPWpGaD
Lamivudine—ABCB1—Allograft Rejection—IL17A—psoriasis	0.000103	0.00278	CbGpPWpGaD
Lamivudine—PCYT1A—Metabolism of lipids and lipoproteins—PPARG—psoriasis	0.0001	0.00271	CbGpPWpGaD
Lamivudine—DCK—Retinoblastoma (RB) in Cancer—TP53—psoriasis	0.0001	0.00271	CbGpPWpGaD
Lamivudine—Insomnia—Hydrocortisone—psoriasis	9.9e-05	0.000319	CcSEcCtD
Lamivudine—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	9.84e-05	0.00266	CbGpPWpGaD
Lamivudine—NME2—Metabolism—CARM1—psoriasis	9.83e-05	0.00265	CbGpPWpGaD
Lamivudine—Paraesthesia—Hydrocortisone—psoriasis	9.83e-05	0.000317	CcSEcCtD
Lamivudine—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	9.82e-05	0.000317	CcSEcCtD
Lamivudine—Urticaria—Cyclosporine—psoriasis	9.78e-05	0.000315	CcSEcCtD
Lamivudine—Myalgia—Dexamethasone—psoriasis	9.75e-05	0.000314	CcSEcCtD
Lamivudine—Myalgia—Betamethasone—psoriasis	9.75e-05	0.000314	CcSEcCtD
Lamivudine—Body temperature increased—Cyclosporine—psoriasis	9.73e-05	0.000314	CcSEcCtD
Lamivudine—Abdominal pain—Cyclosporine—psoriasis	9.73e-05	0.000314	CcSEcCtD
Lamivudine—Anxiety—Betamethasone—psoriasis	9.72e-05	0.000313	CcSEcCtD
Lamivudine—Anxiety—Dexamethasone—psoriasis	9.72e-05	0.000313	CcSEcCtD
Lamivudine—Vomiting—Mycophenolic acid—psoriasis	9.68e-05	0.000312	CcSEcCtD
Lamivudine—Discomfort—Dexamethasone—psoriasis	9.64e-05	0.000311	CcSEcCtD
Lamivudine—Discomfort—Betamethasone—psoriasis	9.64e-05	0.000311	CcSEcCtD
Lamivudine—Dyspepsia—Hydrocortisone—psoriasis	9.63e-05	0.00031	CcSEcCtD
Lamivudine—Rash—Mycophenolic acid—psoriasis	9.6e-05	0.000309	CcSEcCtD
Lamivudine—Dermatitis—Mycophenolic acid—psoriasis	9.59e-05	0.000309	CcSEcCtD
Lamivudine—Pain—Prednisolone—psoriasis	9.58e-05	0.000309	CcSEcCtD
Lamivudine—Hepatitis—Methotrexate—psoriasis	9.58e-05	0.000309	CcSEcCtD
Lamivudine—ABCB1—Allograft Rejection—IL12B—psoriasis	9.57e-05	0.00258	CbGpPWpGaD
Lamivudine—Urticaria—Mycophenolate mofetil—psoriasis	9.54e-05	0.000307	CcSEcCtD
Lamivudine—Headache—Mycophenolic acid—psoriasis	9.54e-05	0.000307	CcSEcCtD
Lamivudine—Decreased appetite—Hydrocortisone—psoriasis	9.51e-05	0.000307	CcSEcCtD
Lamivudine—Pharyngitis—Methotrexate—psoriasis	9.51e-05	0.000306	CcSEcCtD
Lamivudine—Abdominal pain—Mycophenolate mofetil—psoriasis	9.5e-05	0.000306	CcSEcCtD
Lamivudine—Body temperature increased—Mycophenolate mofetil—psoriasis	9.5e-05	0.000306	CcSEcCtD
Lamivudine—Gastrointestinal disorder—Hydrocortisone—psoriasis	9.45e-05	0.000304	CcSEcCtD
Lamivudine—Fatigue—Hydrocortisone—psoriasis	9.44e-05	0.000304	CcSEcCtD
Lamivudine—Musculoskeletal discomfort—Triamcinolone—psoriasis	9.39e-05	0.000303	CcSEcCtD
Lamivudine—Pain—Hydrocortisone—psoriasis	9.36e-05	0.000302	CcSEcCtD
Lamivudine—Oedema—Dexamethasone—psoriasis	9.35e-05	0.000301	CcSEcCtD
Lamivudine—Oedema—Betamethasone—psoriasis	9.35e-05	0.000301	CcSEcCtD
Lamivudine—Anaphylactic shock—Dexamethasone—psoriasis	9.35e-05	0.000301	CcSEcCtD
Lamivudine—Anaphylactic shock—Betamethasone—psoriasis	9.35e-05	0.000301	CcSEcCtD
Lamivudine—ABCB1—Allograft Rejection—HLA-E—psoriasis	9.34e-05	0.00252	CbGpPWpGaD
Lamivudine—Insomnia—Triamcinolone—psoriasis	9.32e-05	0.0003	CcSEcCtD
Lamivudine—Infection—Dexamethasone—psoriasis	9.29e-05	0.000299	CcSEcCtD
Lamivudine—Infection—Betamethasone—psoriasis	9.29e-05	0.000299	CcSEcCtD
Lamivudine—Ill-defined disorder—Prednisone—psoriasis	9.26e-05	0.000298	CcSEcCtD
Lamivudine—Paraesthesia—Triamcinolone—psoriasis	9.25e-05	0.000298	CcSEcCtD
Lamivudine—Feeling abnormal—Prednisolone—psoriasis	9.23e-05	0.000298	CcSEcCtD
Lamivudine—Anaemia—Prednisone—psoriasis	9.22e-05	0.000297	CcSEcCtD
Lamivudine—Shock—Dexamethasone—psoriasis	9.2e-05	0.000296	CcSEcCtD
Lamivudine—Shock—Betamethasone—psoriasis	9.2e-05	0.000296	CcSEcCtD
Lamivudine—Dyspnoea—Triamcinolone—psoriasis	9.19e-05	0.000296	CcSEcCtD
Lamivudine—Nervous system disorder—Dexamethasone—psoriasis	9.17e-05	0.000295	CcSEcCtD
Lamivudine—Nervous system disorder—Betamethasone—psoriasis	9.17e-05	0.000295	CcSEcCtD
Lamivudine—Thrombocytopenia—Betamethasone—psoriasis	9.15e-05	0.000295	CcSEcCtD
Lamivudine—Thrombocytopenia—Dexamethasone—psoriasis	9.15e-05	0.000295	CcSEcCtD
Lamivudine—Angioedema—Prednisone—psoriasis	9.12e-05	0.000294	CcSEcCtD
Lamivudine—Hypersensitivity—Cyclosporine—psoriasis	9.07e-05	0.000292	CcSEcCtD
Lamivudine—Dyspepsia—Triamcinolone—psoriasis	9.07e-05	0.000292	CcSEcCtD
Lamivudine—Erythema multiforme—Methotrexate—psoriasis	9.06e-05	0.000292	CcSEcCtD
Lamivudine—Nausea—Mycophenolic acid—psoriasis	9.04e-05	0.000291	CcSEcCtD
Lamivudine—Hyperhidrosis—Dexamethasone—psoriasis	9.04e-05	0.000291	CcSEcCtD
Lamivudine—Hyperhidrosis—Betamethasone—psoriasis	9.04e-05	0.000291	CcSEcCtD
Lamivudine—Feeling abnormal—Hydrocortisone—psoriasis	9.02e-05	0.000291	CcSEcCtD
Lamivudine—Malaise—Prednisone—psoriasis	9e-05	0.00029	CcSEcCtD
Lamivudine—Vertigo—Prednisone—psoriasis	8.96e-05	0.000289	CcSEcCtD
Lamivudine—Gastrointestinal pain—Hydrocortisone—psoriasis	8.95e-05	0.000288	CcSEcCtD
Lamivudine—Syncope—Prednisone—psoriasis	8.95e-05	0.000288	CcSEcCtD
Lamivudine—Anorexia—Betamethasone—psoriasis	8.91e-05	0.000287	CcSEcCtD
Lamivudine—Anorexia—Dexamethasone—psoriasis	8.91e-05	0.000287	CcSEcCtD
Lamivudine—SLC22A2—SLC-mediated transmembrane transport—CP—psoriasis	8.91e-05	0.0024	CbGpPWpGaD
Lamivudine—Urticaria—Prednisolone—psoriasis	8.9e-05	0.000287	CcSEcCtD
Lamivudine—Fatigue—Triamcinolone—psoriasis	8.88e-05	0.000286	CcSEcCtD
Lamivudine—NME1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	8.85e-05	0.00239	CbGpPWpGaD
Lamivudine—Hypersensitivity—Mycophenolate mofetil—psoriasis	8.85e-05	0.000285	CcSEcCtD
Lamivudine—Asthenia—Cyclosporine—psoriasis	8.84e-05	0.000285	CcSEcCtD
Lamivudine—Pain—Triamcinolone—psoriasis	8.81e-05	0.000284	CcSEcCtD
Lamivudine—Loss of consciousness—Prednisone—psoriasis	8.77e-05	0.000283	CcSEcCtD
Lamivudine—Hypotension—Betamethasone—psoriasis	8.74e-05	0.000282	CcSEcCtD
Lamivudine—Hypotension—Dexamethasone—psoriasis	8.74e-05	0.000282	CcSEcCtD
Lamivudine—ABCG2—Fluoropyrimidine Activity—TP53—psoriasis	8.73e-05	0.00236	CbGpPWpGaD
Lamivudine—NT5C—Metabolism—CAT—psoriasis	8.72e-05	0.00235	CbGpPWpGaD
Lamivudine—PCYT2—Metabolism—CAT—psoriasis	8.72e-05	0.00235	CbGpPWpGaD
Lamivudine—CMPK1—Metabolism—CAT—psoriasis	8.72e-05	0.00235	CbGpPWpGaD
Lamivudine—Pruritus—Cyclosporine—psoriasis	8.71e-05	0.000281	CcSEcCtD
Lamivudine—Urticaria—Hydrocortisone—psoriasis	8.69e-05	0.00028	CcSEcCtD
Lamivudine—Immune system disorder—Methotrexate—psoriasis	8.65e-05	0.000279	CcSEcCtD
Lamivudine—Abdominal pain—Hydrocortisone—psoriasis	8.65e-05	0.000279	CcSEcCtD
Lamivudine—Body temperature increased—Hydrocortisone—psoriasis	8.65e-05	0.000279	CcSEcCtD
Lamivudine—Convulsion—Prednisone—psoriasis	8.64e-05	0.000279	CcSEcCtD
Lamivudine—Mediastinal disorder—Methotrexate—psoriasis	8.63e-05	0.000278	CcSEcCtD
Lamivudine—Asthenia—Mycophenolate mofetil—psoriasis	8.62e-05	0.000278	CcSEcCtD
Lamivudine—Chills—Methotrexate—psoriasis	8.59e-05	0.000277	CcSEcCtD
Lamivudine—Musculoskeletal discomfort—Dexamethasone—psoriasis	8.52e-05	0.000274	CcSEcCtD
Lamivudine—Musculoskeletal discomfort—Betamethasone—psoriasis	8.52e-05	0.000274	CcSEcCtD
Lamivudine—Pruritus—Mycophenolate mofetil—psoriasis	8.5e-05	0.000274	CcSEcCtD
Lamivudine—Myalgia—Prednisone—psoriasis	8.49e-05	0.000274	CcSEcCtD
Lamivudine—Arthralgia—Prednisone—psoriasis	8.49e-05	0.000274	CcSEcCtD
Lamivudine—Feeling abnormal—Triamcinolone—psoriasis	8.49e-05	0.000274	CcSEcCtD
Lamivudine—Anxiety—Prednisone—psoriasis	8.46e-05	0.000273	CcSEcCtD
Lamivudine—Alopecia—Methotrexate—psoriasis	8.46e-05	0.000273	CcSEcCtD
Lamivudine—Insomnia—Betamethasone—psoriasis	8.46e-05	0.000272	CcSEcCtD
Lamivudine—Insomnia—Dexamethasone—psoriasis	8.46e-05	0.000272	CcSEcCtD
Lamivudine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	8.44e-05	0.000272	CcSEcCtD
Lamivudine—Diarrhoea—Cyclosporine—psoriasis	8.43e-05	0.000271	CcSEcCtD
Lamivudine—Paraesthesia—Dexamethasone—psoriasis	8.4e-05	0.000271	CcSEcCtD
Lamivudine—Paraesthesia—Betamethasone—psoriasis	8.4e-05	0.000271	CcSEcCtD
Lamivudine—Discomfort—Prednisone—psoriasis	8.39e-05	0.00027	CcSEcCtD
Lamivudine—Malnutrition—Methotrexate—psoriasis	8.34e-05	0.000269	CcSEcCtD
Lamivudine—Erythema—Methotrexate—psoriasis	8.34e-05	0.000269	CcSEcCtD
Lamivudine—SLC22A1—SLC-mediated transmembrane transport—CP—psoriasis	8.31e-05	0.00224	CbGpPWpGaD
Lamivudine—Hypersensitivity—Prednisolone—psoriasis	8.26e-05	0.000266	CcSEcCtD
Lamivudine—Dyspepsia—Dexamethasone—psoriasis	8.23e-05	0.000265	CcSEcCtD
Lamivudine—Dyspepsia—Betamethasone—psoriasis	8.23e-05	0.000265	CcSEcCtD
Lamivudine—Diarrhoea—Mycophenolate mofetil—psoriasis	8.22e-05	0.000265	CcSEcCtD
Lamivudine—Urticaria—Triamcinolone—psoriasis	8.19e-05	0.000264	CcSEcCtD
Lamivudine—Dysgeusia—Methotrexate—psoriasis	8.17e-05	0.000263	CcSEcCtD
Lamivudine—Body temperature increased—Triamcinolone—psoriasis	8.15e-05	0.000262	CcSEcCtD
Lamivudine—Dizziness—Cyclosporine—psoriasis	8.14e-05	0.000262	CcSEcCtD
Lamivudine—Anaphylactic shock—Prednisone—psoriasis	8.14e-05	0.000262	CcSEcCtD
Lamivudine—Oedema—Prednisone—psoriasis	8.14e-05	0.000262	CcSEcCtD
Lamivudine—Decreased appetite—Betamethasone—psoriasis	8.13e-05	0.000262	CcSEcCtD
Lamivudine—Decreased appetite—Dexamethasone—psoriasis	8.13e-05	0.000262	CcSEcCtD
Lamivudine—Infection—Prednisone—psoriasis	8.09e-05	0.000261	CcSEcCtD
Lamivudine—Gastrointestinal disorder—Betamethasone—psoriasis	8.07e-05	0.00026	CcSEcCtD
Lamivudine—Gastrointestinal disorder—Dexamethasone—psoriasis	8.07e-05	0.00026	CcSEcCtD
Lamivudine—Back pain—Methotrexate—psoriasis	8.07e-05	0.00026	CcSEcCtD
Lamivudine—Hypersensitivity—Hydrocortisone—psoriasis	8.06e-05	0.00026	CcSEcCtD
Lamivudine—Fatigue—Dexamethasone—psoriasis	8.06e-05	0.00026	CcSEcCtD
Lamivudine—Fatigue—Betamethasone—psoriasis	8.06e-05	0.00026	CcSEcCtD
Lamivudine—Shock—Prednisone—psoriasis	8.01e-05	0.000258	CcSEcCtD
Lamivudine—Pain—Betamethasone—psoriasis	8e-05	0.000258	CcSEcCtD
Lamivudine—Pain—Dexamethasone—psoriasis	8e-05	0.000258	CcSEcCtD
Lamivudine—Nervous system disorder—Prednisone—psoriasis	7.99e-05	0.000257	CcSEcCtD
Lamivudine—Dizziness—Mycophenolate mofetil—psoriasis	7.94e-05	0.000256	CcSEcCtD
Lamivudine—Skin disorder—Prednisone—psoriasis	7.91e-05	0.000255	CcSEcCtD
Lamivudine—Hyperhidrosis—Prednisone—psoriasis	7.87e-05	0.000254	CcSEcCtD
Lamivudine—Asthenia—Hydrocortisone—psoriasis	7.85e-05	0.000253	CcSEcCtD
Lamivudine—Vomiting—Cyclosporine—psoriasis	7.83e-05	0.000252	CcSEcCtD
Lamivudine—NME1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	7.81e-05	0.00211	CbGpPWpGaD
Lamivudine—SLC22A3—Metabolism—NDUFA5—psoriasis	7.77e-05	0.0021	CbGpPWpGaD
Lamivudine—Rash—Cyclosporine—psoriasis	7.76e-05	0.00025	CcSEcCtD
Lamivudine—Anorexia—Prednisone—psoriasis	7.76e-05	0.00025	CcSEcCtD
Lamivudine—ABCC4—Platelet degranulation—VEGFA—psoriasis	7.76e-05	0.00209	CbGpPWpGaD
Lamivudine—Dermatitis—Cyclosporine—psoriasis	7.76e-05	0.00025	CcSEcCtD
Lamivudine—Pruritus—Hydrocortisone—psoriasis	7.74e-05	0.000249	CcSEcCtD
Lamivudine—Ill-defined disorder—Methotrexate—psoriasis	7.74e-05	0.000249	CcSEcCtD
Lamivudine—ABCB1—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	7.73e-05	0.00209	CbGpPWpGaD
Lamivudine—Headache—Cyclosporine—psoriasis	7.71e-05	0.000249	CcSEcCtD
Lamivudine—Anaemia—Methotrexate—psoriasis	7.71e-05	0.000248	CcSEcCtD
Lamivudine—Feeling abnormal—Betamethasone—psoriasis	7.7e-05	0.000248	CcSEcCtD
Lamivudine—Feeling abnormal—Dexamethasone—psoriasis	7.7e-05	0.000248	CcSEcCtD
Lamivudine—Gastrointestinal pain—Dexamethasone—psoriasis	7.65e-05	0.000246	CcSEcCtD
Lamivudine—Gastrointestinal pain—Betamethasone—psoriasis	7.65e-05	0.000246	CcSEcCtD
Lamivudine—Vomiting—Mycophenolate mofetil—psoriasis	7.64e-05	0.000246	CcSEcCtD
Lamivudine—DCK—Levonorgestrel—Hydrocortisone—psoriasis	7.61e-05	0.0129	CbGdCrCtD
Lamivudine—ABCG2—HIF-1-alpha transcription factor network—JUN—psoriasis	7.6e-05	0.00205	CbGpPWpGaD
Lamivudine—Hypersensitivity—Triamcinolone—psoriasis	7.59e-05	0.000245	CcSEcCtD
Lamivudine—Rash—Mycophenolate mofetil—psoriasis	7.57e-05	0.000244	CcSEcCtD
Lamivudine—Dermatitis—Mycophenolate mofetil—psoriasis	7.57e-05	0.000244	CcSEcCtD
Lamivudine—Headache—Mycophenolate mofetil—psoriasis	7.53e-05	0.000242	CcSEcCtD
Lamivudine—Malaise—Methotrexate—psoriasis	7.52e-05	0.000242	CcSEcCtD
Lamivudine—Vertigo—Methotrexate—psoriasis	7.49e-05	0.000241	CcSEcCtD
Lamivudine—Diarrhoea—Hydrocortisone—psoriasis	7.49e-05	0.000241	CcSEcCtD
Lamivudine—Leukopenia—Methotrexate—psoriasis	7.46e-05	0.00024	CcSEcCtD
Lamivudine—ABCC4—Hemostasis—ITGAL—psoriasis	7.46e-05	0.00201	CbGpPWpGaD
Lamivudine—NME1—Metabolism—CARM1—psoriasis	7.45e-05	0.00201	CbGpPWpGaD
Lamivudine—Urticaria—Dexamethasone—psoriasis	7.43e-05	0.000239	CcSEcCtD
Lamivudine—Urticaria—Betamethasone—psoriasis	7.43e-05	0.000239	CcSEcCtD
Lamivudine—Musculoskeletal discomfort—Prednisone—psoriasis	7.42e-05	0.000239	CcSEcCtD
Lamivudine—Dizziness—Prednisolone—psoriasis	7.41e-05	0.000239	CcSEcCtD
Lamivudine—Asthenia—Triamcinolone—psoriasis	7.39e-05	0.000238	CcSEcCtD
Lamivudine—Body temperature increased—Dexamethasone—psoriasis	7.39e-05	0.000238	CcSEcCtD
Lamivudine—Body temperature increased—Betamethasone—psoriasis	7.39e-05	0.000238	CcSEcCtD
Lamivudine—Abdominal pain—Betamethasone—psoriasis	7.39e-05	0.000238	CcSEcCtD
Lamivudine—Abdominal pain—Dexamethasone—psoriasis	7.39e-05	0.000238	CcSEcCtD
Lamivudine—ABCC4—Response to elevated platelet cytosolic Ca2+—VEGFA—psoriasis	7.39e-05	0.00199	CbGpPWpGaD
Lamivudine—Insomnia—Prednisone—psoriasis	7.36e-05	0.000237	CcSEcCtD
Lamivudine—Nausea—Cyclosporine—psoriasis	7.31e-05	0.000236	CcSEcCtD
Lamivudine—Paraesthesia—Prednisone—psoriasis	7.31e-05	0.000236	CcSEcCtD
Lamivudine—Pruritus—Triamcinolone—psoriasis	7.29e-05	0.000235	CcSEcCtD
Lamivudine—Cough—Methotrexate—psoriasis	7.28e-05	0.000234	CcSEcCtD
Lamivudine—Dizziness—Hydrocortisone—psoriasis	7.24e-05	0.000233	CcSEcCtD
Lamivudine—Convulsion—Methotrexate—psoriasis	7.22e-05	0.000233	CcSEcCtD
Lamivudine—SLC22A3—Transmembrane transport of small molecules—CP—psoriasis	7.22e-05	0.00195	CbGpPWpGaD
Lamivudine—Dyspepsia—Prednisone—psoriasis	7.17e-05	0.000231	CcSEcCtD
Lamivudine—ABCC3—Metabolism—NDUFA5—psoriasis	7.14e-05	0.00193	CbGpPWpGaD
Lamivudine—Nausea—Mycophenolate mofetil—psoriasis	7.14e-05	0.00023	CcSEcCtD
Lamivudine—PGK1—Metabolism—CAT—psoriasis	7.11e-05	0.00192	CbGpPWpGaD
Lamivudine—Arthralgia—Methotrexate—psoriasis	7.1e-05	0.000229	CcSEcCtD
Lamivudine—Myalgia—Methotrexate—psoriasis	7.1e-05	0.000229	CcSEcCtD
Lamivudine—Chest pain—Methotrexate—psoriasis	7.1e-05	0.000229	CcSEcCtD
Lamivudine—Decreased appetite—Prednisone—psoriasis	7.08e-05	0.000228	CcSEcCtD
Lamivudine—PGK1—Disease—HLA-A—psoriasis	7.07e-05	0.00191	CbGpPWpGaD
Lamivudine—Rash—Prednisolone—psoriasis	7.07e-05	0.000228	CcSEcCtD
Lamivudine—Dermatitis—Prednisolone—psoriasis	7.06e-05	0.000227	CcSEcCtD
Lamivudine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	7.05e-05	0.000227	CcSEcCtD
Lamivudine—Fatigue—Prednisone—psoriasis	7.02e-05	0.000226	CcSEcCtD
Lamivudine—Headache—Prednisolone—psoriasis	7.02e-05	0.000226	CcSEcCtD
Lamivudine—Discomfort—Methotrexate—psoriasis	7.01e-05	0.000226	CcSEcCtD
Lamivudine—ABCB1—Allograft Rejection—IL10—psoriasis	7e-05	0.00189	CbGpPWpGaD
Lamivudine—Constipation—Prednisone—psoriasis	6.96e-05	0.000224	CcSEcCtD
Lamivudine—Vomiting—Hydrocortisone—psoriasis	6.96e-05	0.000224	CcSEcCtD
Lamivudine—Rash—Hydrocortisone—psoriasis	6.9e-05	0.000222	CcSEcCtD
Lamivudine—Dermatitis—Hydrocortisone—psoriasis	6.89e-05	0.000222	CcSEcCtD
Lamivudine—SLC22A3—Transmembrane transport of small molecules—CARM1—psoriasis	6.89e-05	0.00186	CbGpPWpGaD
Lamivudine—Confusional state—Methotrexate—psoriasis	6.86e-05	0.000221	CcSEcCtD
Lamivudine—Headache—Hydrocortisone—psoriasis	6.86e-05	0.000221	CcSEcCtD
Lamivudine—Dizziness—Triamcinolone—psoriasis	6.81e-05	0.00022	CcSEcCtD
Lamivudine—ABCB1—Allograft Rejection—IL4—psoriasis	6.81e-05	0.00184	CbGpPWpGaD
Lamivudine—Anaphylactic shock—Methotrexate—psoriasis	6.81e-05	0.000219	CcSEcCtD
Lamivudine—PCYT2—Metabolism—APOE—psoriasis	6.78e-05	0.00183	CbGpPWpGaD
Lamivudine—CMPK1—Metabolism—APOE—psoriasis	6.78e-05	0.00183	CbGpPWpGaD
Lamivudine—NT5C—Metabolism—APOE—psoriasis	6.78e-05	0.00183	CbGpPWpGaD
Lamivudine—Infection—Methotrexate—psoriasis	6.76e-05	0.000218	CcSEcCtD
Lamivudine—Feeling abnormal—Prednisone—psoriasis	6.71e-05	0.000216	CcSEcCtD
Lamivudine—Asthenia—Betamethasone—psoriasis	6.71e-05	0.000216	CcSEcCtD
Lamivudine—Asthenia—Dexamethasone—psoriasis	6.71e-05	0.000216	CcSEcCtD
Lamivudine—Nervous system disorder—Methotrexate—psoriasis	6.67e-05	0.000215	CcSEcCtD
Lamivudine—Thrombocytopenia—Methotrexate—psoriasis	6.66e-05	0.000215	CcSEcCtD
Lamivudine—ABCC3—Metabolism of lipids and lipoproteins—CARM1—psoriasis	6.66e-05	0.0018	CbGpPWpGaD
Lamivudine—Gastrointestinal pain—Prednisone—psoriasis	6.66e-05	0.000215	CcSEcCtD
Lamivudine—Nausea—Prednisolone—psoriasis	6.66e-05	0.000214	CcSEcCtD
Lamivudine—ABCB1—Allograft Rejection—HLA-B—psoriasis	6.65e-05	0.0018	CbGpPWpGaD
Lamivudine—ABCB1—HIF-1-alpha transcription factor network—LEP—psoriasis	6.65e-05	0.00179	CbGpPWpGaD
Lamivudine—ABCC3—Transmembrane transport of small molecules—CP—psoriasis	6.64e-05	0.00179	CbGpPWpGaD
Lamivudine—ABCG2—HIF-1-alpha transcription factor network—VEGFA—psoriasis	6.64e-05	0.00179	CbGpPWpGaD
Lamivudine—Pruritus—Betamethasone—psoriasis	6.62e-05	0.000213	CcSEcCtD
Lamivudine—Pruritus—Dexamethasone—psoriasis	6.62e-05	0.000213	CcSEcCtD
Lamivudine—Skin disorder—Methotrexate—psoriasis	6.61e-05	0.000213	CcSEcCtD
Lamivudine—PCYT1A—Metabolism—CAT—psoriasis	6.61e-05	0.00178	CbGpPWpGaD
Lamivudine—SLC22A3—Metabolism—CYP2S1—psoriasis	6.61e-05	0.00178	CbGpPWpGaD
Lamivudine—PGK1—Disease—APOE—psoriasis	6.6e-05	0.00178	CbGpPWpGaD
Lamivudine—Hyperhidrosis—Methotrexate—psoriasis	6.58e-05	0.000212	CcSEcCtD
Lamivudine—Vomiting—Triamcinolone—psoriasis	6.55e-05	0.000211	CcSEcCtD
Lamivudine—Nausea—Hydrocortisone—psoriasis	6.5e-05	0.000209	CcSEcCtD
Lamivudine—Rash—Triamcinolone—psoriasis	6.5e-05	0.000209	CcSEcCtD
Lamivudine—Dermatitis—Triamcinolone—psoriasis	6.49e-05	0.000209	CcSEcCtD
Lamivudine—Anorexia—Methotrexate—psoriasis	6.49e-05	0.000209	CcSEcCtD
Lamivudine—Urticaria—Prednisone—psoriasis	6.47e-05	0.000208	CcSEcCtD
Lamivudine—Headache—Triamcinolone—psoriasis	6.46e-05	0.000208	CcSEcCtD
Lamivudine—Abdominal pain—Prednisone—psoriasis	6.44e-05	0.000207	CcSEcCtD
Lamivudine—Body temperature increased—Prednisone—psoriasis	6.44e-05	0.000207	CcSEcCtD
Lamivudine—Diarrhoea—Dexamethasone—psoriasis	6.4e-05	0.000206	CcSEcCtD
Lamivudine—Diarrhoea—Betamethasone—psoriasis	6.4e-05	0.000206	CcSEcCtD
Lamivudine—Hypotension—Methotrexate—psoriasis	6.36e-05	0.000205	CcSEcCtD
Lamivudine—ABCC3—Transmembrane transport of small molecules—CARM1—psoriasis	6.33e-05	0.00171	CbGpPWpGaD
Lamivudine—ABCC4—Transmembrane transport of small molecules—CP—psoriasis	6.24e-05	0.00168	CbGpPWpGaD
Lamivudine—Musculoskeletal discomfort—Methotrexate—psoriasis	6.2e-05	0.0002	CcSEcCtD
Lamivudine—ABCB1—HIF-1-alpha transcription factor network—NOS2—psoriasis	6.19e-05	0.00167	CbGpPWpGaD
Lamivudine—Dizziness—Betamethasone—psoriasis	6.18e-05	0.000199	CcSEcCtD
Lamivudine—Dizziness—Dexamethasone—psoriasis	6.18e-05	0.000199	CcSEcCtD
Lamivudine—ABCB1—Allograft Rejection—HLA-A—psoriasis	6.17e-05	0.00166	CbGpPWpGaD
Lamivudine—Insomnia—Methotrexate—psoriasis	6.15e-05	0.000198	CcSEcCtD
Lamivudine—PGK1—Disease—NOS2—psoriasis	6.15e-05	0.00166	CbGpPWpGaD
Lamivudine—Nausea—Triamcinolone—psoriasis	6.12e-05	0.000197	CcSEcCtD
Lamivudine—Paraesthesia—Methotrexate—psoriasis	6.11e-05	0.000197	CcSEcCtD
Lamivudine—ABCC3—Metabolism—CYP2S1—psoriasis	6.07e-05	0.00164	CbGpPWpGaD
Lamivudine—Dyspnoea—Methotrexate—psoriasis	6.07e-05	0.000195	CcSEcCtD
Lamivudine—Somnolence—Methotrexate—psoriasis	6.05e-05	0.000195	CcSEcCtD
Lamivudine—NME2—Metabolism—CAT—psoriasis	6.05e-05	0.00163	CbGpPWpGaD
Lamivudine—Hypersensitivity—Prednisone—psoriasis	6e-05	0.000193	CcSEcCtD
Lamivudine—Dyspepsia—Methotrexate—psoriasis	5.99e-05	0.000193	CcSEcCtD
Lamivudine—ABCC4—Transmembrane transport of small molecules—CARM1—psoriasis	5.95e-05	0.00161	CbGpPWpGaD
Lamivudine—Vomiting—Dexamethasone—psoriasis	5.94e-05	0.000192	CcSEcCtD
Lamivudine—Vomiting—Betamethasone—psoriasis	5.94e-05	0.000192	CcSEcCtD
Lamivudine—Decreased appetite—Methotrexate—psoriasis	5.92e-05	0.000191	CcSEcCtD
Lamivudine—CMPK1—Metabolism—PPARG—psoriasis	5.9e-05	0.00159	CbGpPWpGaD
Lamivudine—PCYT2—Metabolism—PPARG—psoriasis	5.9e-05	0.00159	CbGpPWpGaD
Lamivudine—NT5C—Metabolism—PPARG—psoriasis	5.9e-05	0.00159	CbGpPWpGaD
Lamivudine—Rash—Betamethasone—psoriasis	5.9e-05	0.00019	CcSEcCtD
Lamivudine—Rash—Dexamethasone—psoriasis	5.9e-05	0.00019	CcSEcCtD
Lamivudine—Dermatitis—Betamethasone—psoriasis	5.89e-05	0.00019	CcSEcCtD
Lamivudine—Dermatitis—Dexamethasone—psoriasis	5.89e-05	0.00019	CcSEcCtD
Lamivudine—Gastrointestinal disorder—Methotrexate—psoriasis	5.88e-05	0.000189	CcSEcCtD
Lamivudine—Fatigue—Methotrexate—psoriasis	5.87e-05	0.000189	CcSEcCtD
Lamivudine—Headache—Betamethasone—psoriasis	5.86e-05	0.000189	CcSEcCtD
Lamivudine—Headache—Dexamethasone—psoriasis	5.86e-05	0.000189	CcSEcCtD
Lamivudine—Asthenia—Prednisone—psoriasis	5.84e-05	0.000188	CcSEcCtD
Lamivudine—Pain—Methotrexate—psoriasis	5.82e-05	0.000188	CcSEcCtD
Lamivudine—Pruritus—Prednisone—psoriasis	5.76e-05	0.000186	CcSEcCtD
Lamivudine—ABCB1—Allograft Rejection—HLA-DRB1—psoriasis	5.63e-05	0.00152	CbGpPWpGaD
Lamivudine—Feeling abnormal—Methotrexate—psoriasis	5.61e-05	0.000181	CcSEcCtD
Lamivudine—ABCC1—Metabolism—NDUFA5—psoriasis	5.6e-05	0.00151	CbGpPWpGaD
Lamivudine—Diarrhoea—Prednisone—psoriasis	5.57e-05	0.00018	CcSEcCtD
Lamivudine—Gastrointestinal pain—Methotrexate—psoriasis	5.56e-05	0.000179	CcSEcCtD
Lamivudine—Nausea—Betamethasone—psoriasis	5.55e-05	0.000179	CcSEcCtD
Lamivudine—Nausea—Dexamethasone—psoriasis	5.55e-05	0.000179	CcSEcCtD
Lamivudine—PGK1—Metabolism—APOE—psoriasis	5.52e-05	0.00149	CbGpPWpGaD
Lamivudine—SLC22A6—Transmembrane transport of small molecules—CP—psoriasis	5.43e-05	0.00147	CbGpPWpGaD
Lamivudine—Urticaria—Methotrexate—psoriasis	5.41e-05	0.000174	CcSEcCtD
Lamivudine—Dizziness—Prednisone—psoriasis	5.38e-05	0.000173	CcSEcCtD
Lamivudine—Body temperature increased—Methotrexate—psoriasis	5.38e-05	0.000173	CcSEcCtD
Lamivudine—Abdominal pain—Methotrexate—psoriasis	5.38e-05	0.000173	CcSEcCtD
Lamivudine—ABCC2—Transmembrane transport of small molecules—CP—psoriasis	5.26e-05	0.00142	CbGpPWpGaD
Lamivudine—ABCC1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	5.22e-05	0.00141	CbGpPWpGaD
Lamivudine—ABCC1—Transmembrane transport of small molecules—CP—psoriasis	5.2e-05	0.0014	CbGpPWpGaD
Lamivudine—SLC22A6—Transmembrane transport of small molecules—CARM1—psoriasis	5.18e-05	0.0014	CbGpPWpGaD
Lamivudine—Vomiting—Prednisone—psoriasis	5.18e-05	0.000167	CcSEcCtD
Lamivudine—PCYT1A—Metabolism—APOE—psoriasis	5.14e-05	0.00139	CbGpPWpGaD
Lamivudine—Rash—Prednisone—psoriasis	5.13e-05	0.000165	CcSEcCtD
Lamivudine—Dermatitis—Prednisone—psoriasis	5.13e-05	0.000165	CcSEcCtD
Lamivudine—DCK—Metabolism—CARM1—psoriasis	5.11e-05	0.00138	CbGpPWpGaD
Lamivudine—Headache—Prednisone—psoriasis	5.1e-05	0.000164	CcSEcCtD
Lamivudine—PGK1—Disease—TYK2—psoriasis	5.03e-05	0.00136	CbGpPWpGaD
Lamivudine—ABCC2—Transmembrane transport of small molecules—CARM1—psoriasis	5.02e-05	0.00135	CbGpPWpGaD
Lamivudine—Hypersensitivity—Methotrexate—psoriasis	5.01e-05	0.000162	CcSEcCtD
Lamivudine—ABCC1—Transmembrane transport of small molecules—CARM1—psoriasis	4.96e-05	0.00134	CbGpPWpGaD
Lamivudine—ABCG2—Metabolism—NDUFA5—psoriasis	4.92e-05	0.00133	CbGpPWpGaD
Lamivudine—Asthenia—Methotrexate—psoriasis	4.88e-05	0.000157	CcSEcCtD
Lamivudine—SLC22A2—Metabolism—NDUFA5—psoriasis	4.87e-05	0.00131	CbGpPWpGaD
Lamivudine—Nausea—Prednisone—psoriasis	4.84e-05	0.000156	CcSEcCtD
Lamivudine—Pruritus—Methotrexate—psoriasis	4.81e-05	0.000155	CcSEcCtD
Lamivudine—PGK1—Metabolism—PPARG—psoriasis	4.81e-05	0.0013	CbGpPWpGaD
Lamivudine—ABCC1—Metabolism—CYP2S1—psoriasis	4.76e-05	0.00128	CbGpPWpGaD
Lamivudine—NME2—Metabolism—APOE—psoriasis	4.7e-05	0.00127	CbGpPWpGaD
Lamivudine—Diarrhoea—Methotrexate—psoriasis	4.66e-05	0.00015	CcSEcCtD
Lamivudine—NME1—Metabolism—CAT—psoriasis	4.58e-05	0.00124	CbGpPWpGaD
Lamivudine—ABCG2—Transmembrane transport of small molecules—CP—psoriasis	4.58e-05	0.00123	CbGpPWpGaD
Lamivudine—PGK1—Disease—CD4—psoriasis	4.55e-05	0.00123	CbGpPWpGaD
Lamivudine—SLC22A1—Metabolism—NDUFA5—psoriasis	4.54e-05	0.00123	CbGpPWpGaD
Lamivudine—SLC22A2—Transmembrane transport of small molecules—CP—psoriasis	4.53e-05	0.00122	CbGpPWpGaD
Lamivudine—Dizziness—Methotrexate—psoriasis	4.5e-05	0.000145	CcSEcCtD
Lamivudine—PCYT1A—Metabolism—PPARG—psoriasis	4.47e-05	0.00121	CbGpPWpGaD
Lamivudine—ABCG2—Transmembrane transport of small molecules—CARM1—psoriasis	4.37e-05	0.00118	CbGpPWpGaD
Lamivudine—Vomiting—Methotrexate—psoriasis	4.33e-05	0.000139	CcSEcCtD
Lamivudine—SLC22A2—Transmembrane transport of small molecules—CARM1—psoriasis	4.32e-05	0.00117	CbGpPWpGaD
Lamivudine—Rash—Methotrexate—psoriasis	4.29e-05	0.000138	CcSEcCtD
Lamivudine—Dermatitis—Methotrexate—psoriasis	4.29e-05	0.000138	CcSEcCtD
Lamivudine—Headache—Methotrexate—psoriasis	4.26e-05	0.000137	CcSEcCtD
Lamivudine—SLC22A1—Transmembrane transport of small molecules—CP—psoriasis	4.22e-05	0.00114	CbGpPWpGaD
Lamivudine—ABCG2—Metabolism—CYP2S1—psoriasis	4.19e-05	0.00113	CbGpPWpGaD
Lamivudine—SLC22A2—Metabolism—CYP2S1—psoriasis	4.14e-05	0.00112	CbGpPWpGaD
Lamivudine—ABCB1—Allograft Rejection—IFNG—psoriasis	4.11e-05	0.00111	CbGpPWpGaD
Lamivudine—ABCB1—HIF-1-alpha transcription factor network—JUN—psoriasis	4.11e-05	0.00111	CbGpPWpGaD
Lamivudine—NME2—Metabolism—PPARG—psoriasis	4.09e-05	0.0011	CbGpPWpGaD
Lamivudine—Nausea—Methotrexate—psoriasis	4.04e-05	0.00013	CcSEcCtD
Lamivudine—SLC22A1—Transmembrane transport of small molecules—CARM1—psoriasis	4.03e-05	0.00109	CbGpPWpGaD
Lamivudine—SLC22A1—Metabolism—CYP2S1—psoriasis	3.86e-05	0.00104	CbGpPWpGaD
Lamivudine—ABCB1—Allograft Rejection—CXCL8—psoriasis	3.83e-05	0.00103	CbGpPWpGaD
Lamivudine—ABCB1—HIF-1-alpha transcription factor network—VEGFA—psoriasis	3.59e-05	0.000968	CbGpPWpGaD
Lamivudine—NME1—Metabolism—APOE—psoriasis	3.56e-05	0.000961	CbGpPWpGaD
Lamivudine—PGK1—Disease—STAT3—psoriasis	3.53e-05	0.000951	CbGpPWpGaD
Lamivudine—ABCC4—Platelet activation, signaling and aggregation—VEGFA—psoriasis	3.44e-05	0.000929	CbGpPWpGaD
Lamivudine—SLC22A3—Metabolism—CARM1—psoriasis	3.23e-05	0.000871	CbGpPWpGaD
Lamivudine—ABCC3—Metabolism of lipids and lipoproteins—APOE—psoriasis	3.18e-05	0.000859	CbGpPWpGaD
Lamivudine—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	3.15e-05	0.00085	CbGpPWpGaD
Lamivudine—DCK—Metabolism—CAT—psoriasis	3.14e-05	0.000848	CbGpPWpGaD
Lamivudine—ABCB1—Allograft Rejection—VEGFA—psoriasis	3.11e-05	0.000838	CbGpPWpGaD
Lamivudine—NME1—Metabolism—PPARG—psoriasis	3.1e-05	0.000837	CbGpPWpGaD
Lamivudine—ABCC4—Hemostasis—NOS2—psoriasis	3.06e-05	0.000826	CbGpPWpGaD
Lamivudine—ABCC3—Metabolism—CARM1—psoriasis	2.97e-05	0.0008	CbGpPWpGaD
Lamivudine—ABCC3—Metabolism of lipids and lipoproteins—PPARG—psoriasis	2.77e-05	0.000748	CbGpPWpGaD
Lamivudine—ABCB1—Allograft Rejection—TNF—psoriasis	2.66e-05	0.000718	CbGpPWpGaD
Lamivudine—ABCB1—Metabolism—NDUFA5—psoriasis	2.66e-05	0.000718	CbGpPWpGaD
Lamivudine—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	2.65e-05	0.000714	CbGpPWpGaD
Lamivudine—ABCC1—Metabolism of lipids and lipoproteins—APOE—psoriasis	2.49e-05	0.000673	CbGpPWpGaD
Lamivudine—ABCB1—Transmembrane transport of small molecules—CP—psoriasis	2.47e-05	0.000668	CbGpPWpGaD
Lamivudine—PGK1—Disease—IL6—psoriasis	2.46e-05	0.000664	CbGpPWpGaD
Lamivudine—DCK—Metabolism—APOE—psoriasis	2.44e-05	0.000659	CbGpPWpGaD
Lamivudine—ABCB1—Transmembrane transport of small molecules—CARM1—psoriasis	2.36e-05	0.000637	CbGpPWpGaD
Lamivudine—ABCC1—Metabolism—CARM1—psoriasis	2.32e-05	0.000627	CbGpPWpGaD
Lamivudine—ABCB1—Metabolism—CYP2S1—psoriasis	2.26e-05	0.000611	CbGpPWpGaD
Lamivudine—ABCC1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	2.17e-05	0.000586	CbGpPWpGaD
Lamivudine—DCK—Metabolism—PPARG—psoriasis	2.13e-05	0.000574	CbGpPWpGaD
Lamivudine—ABCG2—Metabolism—CARM1—psoriasis	2.04e-05	0.000552	CbGpPWpGaD
Lamivudine—SLC22A2—Metabolism—CARM1—psoriasis	2.02e-05	0.000546	CbGpPWpGaD
Lamivudine—SLC22A3—Metabolism—CAT—psoriasis	1.98e-05	0.000535	CbGpPWpGaD
Lamivudine—SLC22A1—Metabolism—CARM1—psoriasis	1.89e-05	0.000509	CbGpPWpGaD
Lamivudine—ABCC3—Metabolism—CAT—psoriasis	1.82e-05	0.000492	CbGpPWpGaD
Lamivudine—ABCC4—Hemostasis—VEGFA—psoriasis	1.77e-05	0.000479	CbGpPWpGaD
Lamivudine—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	1.76e-05	0.000474	CbGpPWpGaD
Lamivudine—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	1.69e-05	0.000456	CbGpPWpGaD
Lamivudine—SLC22A3—Metabolism—APOE—psoriasis	1.54e-05	0.000416	CbGpPWpGaD
Lamivudine—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	1.53e-05	0.000414	CbGpPWpGaD
Lamivudine—ABCC1—Metabolism—CAT—psoriasis	1.43e-05	0.000386	CbGpPWpGaD
Lamivudine—ABCC1—Disease—HLA-A—psoriasis	1.42e-05	0.000383	CbGpPWpGaD
Lamivudine—ABCC3—Metabolism—APOE—psoriasis	1.42e-05	0.000382	CbGpPWpGaD
Lamivudine—SLC22A3—Metabolism—PPARG—psoriasis	1.34e-05	0.000362	CbGpPWpGaD
Lamivudine—ABCC4—Hemostasis—TP53—psoriasis	1.34e-05	0.000362	CbGpPWpGaD
Lamivudine—ABCC1—Disease—APOE—psoriasis	1.33e-05	0.000358	CbGpPWpGaD
Lamivudine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	1.31e-05	0.000355	CbGpPWpGaD
Lamivudine—ABCG2—Metabolism—CAT—psoriasis	1.26e-05	0.000339	CbGpPWpGaD
Lamivudine—SLC22A2—Metabolism—CAT—psoriasis	1.24e-05	0.000336	CbGpPWpGaD
Lamivudine—ABCC1—Disease—NOS2—psoriasis	1.24e-05	0.000333	CbGpPWpGaD
Lamivudine—ABCC3—Metabolism—PPARG—psoriasis	1.23e-05	0.000333	CbGpPWpGaD
Lamivudine—SLC22A1—Metabolism—CAT—psoriasis	1.16e-05	0.000313	CbGpPWpGaD
Lamivudine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	1.16e-05	0.000313	CbGpPWpGaD
Lamivudine—ABCC1—Metabolism—APOE—psoriasis	1.11e-05	0.0003	CbGpPWpGaD
Lamivudine—ABCB1—Metabolism—CARM1—psoriasis	1.11e-05	0.000298	CbGpPWpGaD
Lamivudine—ABCC1—Disease—TYK2—psoriasis	1.01e-05	0.000273	CbGpPWpGaD
Lamivudine—ABCG2—Metabolism—APOE—psoriasis	9.77e-06	0.000264	CbGpPWpGaD
Lamivudine—ABCC1—Metabolism—PPARG—psoriasis	9.67e-06	0.000261	CbGpPWpGaD
Lamivudine—SLC22A2—Metabolism—APOE—psoriasis	9.67e-06	0.000261	CbGpPWpGaD
Lamivudine—ABCC1—Disease—CD4—psoriasis	9.15e-06	0.000247	CbGpPWpGaD
Lamivudine—SLC22A1—Metabolism—APOE—psoriasis	9.01e-06	0.000243	CbGpPWpGaD
Lamivudine—ABCG2—Metabolism—PPARG—psoriasis	8.51e-06	0.00023	CbGpPWpGaD
Lamivudine—SLC22A2—Metabolism—PPARG—psoriasis	8.42e-06	0.000227	CbGpPWpGaD
Lamivudine—SLC22A1—Metabolism—PPARG—psoriasis	7.85e-06	0.000212	CbGpPWpGaD
Lamivudine—ABCC1—Disease—STAT3—psoriasis	7.09e-06	0.000191	CbGpPWpGaD
Lamivudine—ABCB1—Metabolism—CAT—psoriasis	6.8e-06	0.000183	CbGpPWpGaD
Lamivudine—ABCB1—Metabolism—APOE—psoriasis	5.28e-06	0.000143	CbGpPWpGaD
Lamivudine—ABCC1—Disease—IL6—psoriasis	4.95e-06	0.000134	CbGpPWpGaD
Lamivudine—ABCB1—Metabolism—PPARG—psoriasis	4.6e-06	0.000124	CbGpPWpGaD
